The global drug discovery market size was valued at USD 111.93 billion in 2025 and is projected to grow from USD 118.53 billion in 2026 to USD 187.50 billion by 2034, registering a CAGR of 5.9% during the forecast period from 2026 to 2034. North America dominated the drug discovery market with a market share of 42.5% in 2025.
Drug discovery is the systematic process of identifying and developing new molecules that exhibit therapeutic potential. It typically involves a combination of scientific research, screening of chemical compounds, and testing to identify compounds with potential therapeutic effects. This process includes stages such as target identification, lead compound discovery, preclinical testing, and ultimately, clinical trials, with the aim of developing safe and effective drugs for treating various diseases.
Download a Free Sample To learn more about this report,
Rising Adoption of AI-Native Drug Discovery Platforms
Artificial intelligence is moving from an experimental research tool toward a core part of pharmaceutical discovery workflows. Generative AI, machine learning, molecular simulation, virtual screening, and predictive models allow researchers to evaluate large chemical spaces, prioritize therapeutic targets, design molecules, and predict drug properties before extensive laboratory testing. These capabilities can reduce repetitive experimentation and allow research teams to concentrate resources on candidates with stronger predicted characteristics.
The growing commercial value of AI-discovery partnerships demonstrates how drug discovery market trends are shifting toward computationally assisted target identification and molecule design.
Growing Pharmaceutical Partnerships with Specialized Discovery Companies
Large pharmaceutical companies are increasingly collaborating with specialized biotechnology and AI companies rather than developing every discovery capability internally. These partnerships provide access to proprietary biological datasets, disease models, computational platforms, and specialist scientific expertise. The approach allows pharmaceutical companies to broaden early-stage pipelines while sharing some of the technological and scientific risks associated with internal platform development.
Increasing collaboration between pharmaceutical companies and specialized technology providers is broadening the drug discovery industry ecosystem and creating new commercial models for early-stage research.
Expansion of Genomics and Multi-Omics Research
Genomics, transcriptomics, proteomics, metabolomics, and other omics technologies are generating increasingly detailed information about disease biology. Combining these datasets allows researchers to identify disease-associated pathways, discover biomarkers, classify patient populations, and select therapeutic targets more precisely. AI and advanced analytics further improve the ability to interpret complex biological datasets that would be difficult to analyze manually.
The increasing availability of genomic and multimodal biological information is strengthening drug discovery market demand for sequencing platforms, bioinformatics, biomarkers, computational biology, and precision-medicine technologies.
Greater integration of multi-omics information is supporting drug discovery market growth by allowing researchers to make more evidence-based decisions during target identification and validation.
High Attrition Rates and Scientific Uncertainty
Drug discovery remains inherently risky because promising laboratory findings do not always translate into safe and effective medicines. Candidates can fail because of toxicity, insufficient efficacy, poor pharmacokinetic characteristics, unexpected biological effects, or difficulty reproducing early findings in humans. Each unsuccessful program can represent years of research and substantial financial investment.
The problem is particularly significant for biotechnology companies with limited pipelines because failure of one major candidate can substantially affect funding, valuations, and future research programs.
Persistent attrition increases the effective cost of successful medicines and remains an important restraint on expansion of the drug discovery market size.
Expansion of Human-Derived Data and AI Foundation Models
The combination of large human biological datasets with increasingly sophisticated AI foundation models represents a major opportunity for drug discovery companies. Human genetic, cellular, clinical, and molecular information can help researchers understand disease mechanisms and identify targets that have stronger biological evidence before significant resources are committed to drug development.
Foundation models trained on biological information can also help predict cellular responses to genetic or pharmacological interventions. This creates opportunities for AI biotechnology companies, sequencing providers, data-platform developers, pharmaceutical companies, and specialized research organizations.
The increasing commercial value assigned to computational discovery platforms creates opportunities for specialized companies to capture greater drug discovery market share through proprietary datasets, models, algorithms, and validated drug candidates.
Managing Intellectual Property in AI-Enabled Drug Discovery
The growing use of AI introduces new intellectual-property questions around ownership of algorithms, training data, molecular designs, therapeutic targets, and discoveries generated through collaborations. Pharmaceutical companies must determine how intellectual property is allocated when several organizations contribute biological datasets, AI platforms, computational models, laboratory validation, and clinical-development expertise.
Patent protection remains particularly important because companies need sufficient exclusivity to recover the substantial costs associated with discovering and developing medicines. At the same time, overlapping patents and disputes over biologic products demonstrate the complexity of protecting pharmaceutical innovation.
As AI-driven partnerships become more common, establishing clear ownership of data, models, targets, molecules, and downstream commercialization rights will become increasingly important for the drug discovery industry.
The market is segmented into small-molecule drugs and biologic drugs. Small-molecule drugs dominated the global market, accounting for 61.8% of the market share, valued at USD 69.17 billion in 2025, owing to their well-established manufacturing processes, lower production costs, broad therapeutic applications, and widespread regulatory approvals. Small-molecule drugs continue to play a vital role in treating chronic and infectious diseases due to their oral bioavailability, ease of distribution, and extensive commercial availability.
However, biologic drugs are projected to register the fastest CAGR of 10.6% during the forecast period, driven by rapid advancements in biotechnology and increasing demand for targeted therapies. Biologics provide highly precise mechanisms of action, making them particularly effective for treating complex diseases such as cancer, autoimmune disorders, and genetic disorders. Regulatory agencies such as the U.S. FDA and the European Medicines Agency (EMA) continue to accelerate approvals for innovative biologic therapies, while pharmaceutical companies are significantly expanding investments in biologics research and development.
Request Customizationto receive a tailored report.
The market is segmented into high-throughput screening (HTS), bioinformatics & in-silico modelling, computational drug discovery & drug design, nanotechnology, and others. High-throughput screening (HTS) held the largest market share of 29.4%, reaching USD 32.91 billion in 2025, due to its ability to rapidly evaluate thousands of chemical compounds and identify promising drug candidates. HTS significantly accelerates early-stage drug discovery, improves research efficiency, and reduces development timelines, making it an indispensable technology for pharmaceutical and biotechnology companies.
Meanwhile, computational drug discovery & drug design is expected to witness the highest CAGR of 11.4% during the forecast period, supported by increasing adoption of artificial intelligence, machine learning, molecular modelling, and advanced computational platforms that improve target identification, lead optimization, and predictive drug design while lowering research costs.
Moreover, continuous advancements in HTS technologies continue to reinforce their widespread adoption. For instance, AstraZeneca's collaboration with Charles River Laboratories to integrate advanced high-throughput screening technologies into its drug discovery programs demonstrates the industry's commitment to accelerating pharmaceutical innovation.
The market is categorized into pharmaceutical companies, contract research organizations (CROs), and others. Pharmaceutical companies accounted for the largest market share of 55.7%, valued at USD 62.35 billion in 2025, driven by substantial investments in research and development, advanced drug discovery infrastructure, and the adoption of emerging technologies such as artificial intelligence, genomics, and bioinformatics. Their extensive financial resources and scientific expertise enable them to manage the complete drug development lifecycle, from target discovery and preclinical research to clinical trials and commercialization.
On the other hand, contract research organizations (CROs) are anticipated to register the fastest CAGR of 10.7% during the forecast period, fueled by the growing trend of outsourcing drug discovery and development activities. Pharmaceutical and biotechnology companies increasingly rely on CROs to reduce development costs, accelerate project timelines, access specialized expertise, and improve operational flexibility.
With continued investments in advanced technologies and strategic collaborations, pharmaceutical companies remain at the forefront of innovation, while the expanding role of CROs is reshaping global drug discovery by delivering faster, more efficient, and cost-effective research services.
Speak to an Analystto discuss market opportunities.
North America dominated the drug discovery market with a 42.5% share in 2025, accounting for USD 47.57 billion, and is projected to grow at a CAGR of 8.9% during the forecast period. The region's growth is driven by a robust pharmaceutical industry, advanced research infrastructure, substantial investments in biotechnology and research and development (R&D), and the presence of leading pharmaceutical and biotechnology companies. Strong regulatory support, extensive clinical research capabilities, and increasing demand for innovative therapies further strengthen the region's leadership.
The U.S. market was valued at USD 42.34 billion in 2025. The country dominates the regional market due to the world's largest pharmaceutical industry, significant R&D spending, advanced drug discovery platforms, and a favorable regulatory environment that accelerates innovation. The presence of major pharmaceutical companies, biotechnology firms, and leading research institutions continues to drive market expansion.
Canada's market reached USD 5.23 billion in 2025. Growing investments in biotechnology research, expanding collaborations with global pharmaceutical companies, increasing focus on personalized medicine, and government funding for life sciences research continue to support the country's market growth.
Unlock Regional Insightsto access country-level data, & regional trends.
Europe accounted for 28.3% of the drug discovery market, reaching USD 31.68 billion in 2025, and is expected to register a CAGR of 10.8% during the forecast period. Market growth is supported by strong pharmaceutical manufacturing, increasing biotechnology investments, favorable regulatory frameworks, and continuous innovation in precision medicine and advanced therapeutic development.
Germany's market accounted for USD 8.55 billion in 2025. The country's advanced pharmaceutical sector, world-class research institutions, increasing investments in biotechnology, and leadership in precision medicine continue to strengthen its position as Europe's largest drug discovery market.
The U.K. market was valued at USD 5.70 billion in 2025. Strong academic research, expanding biotechnology startups, increasing clinical research activities, and government initiatives supporting life sciences innovation continue to drive market growth.
Asia-Pacific held 20.7% of the drug discovery market, valued at USD 23.17 billion in 2025, and is projected to grow at a CAGR of 9.9% during the forecast period. Rising pharmaceutical manufacturing, increasing R&D investments, supportive government initiatives, expanding biotechnology industries, and cost-effective drug development capabilities are driving market growth across the region.
China's market reached USD 9.85 billion in 2025. Massive government investments in biotechnology, rapid expansion of pharmaceutical research, increasing collaborations with global pharmaceutical companies, and growing biologics and oncology research continue to accelerate market growth.
Japan's market generated USD 5.56 billion in 2025. Advanced research infrastructure, strong focus on personalized medicine, increasing development of therapies for age-related diseases, and strategic collaborations with global biotechnology companies continue to support market expansion.
Latin America accounted for 5.1% of the drug discovery market, totaling USD 5.71 billion in 2025, and is expected to grow at a CAGR of 7.6% during the forecast period. Increasing pharmaceutical investments, improving healthcare infrastructure, expanding clinical research activities, and rising demand for innovative therapies are supporting regional market growth.
Brazil's market was valued at USD 2.86 billion in 2025. The country's large pharmaceutical industry, growing biotechnology sector, increasing investments in clinical research, and government support for healthcare innovation continue to drive market expansion.
The Middle East & Africa accounted for 3.4% of the drug discovery market, totaling USD 3.81 billion in 2025, and is anticipated to grow at a CAGR of 6.8% during the forecast period. Growth is supported by improving healthcare infrastructure, increasing investments in pharmaceutical research, expanding biotechnology capabilities, and rising government initiatives to strengthen life sciences across the region.
The UAE market was valued at USD 0.95 billion in 2025. Government investments in biotechnology, expanding pharmaceutical research centers, increasing collaborations with international drug developers, and the development of advanced healthcare infrastructure continue to support market growth.
The global drug discovery industry is moderately fragmented in nature due to the presence of established pharmaceutical companies, biotechnology firms, contract research organizations, and specialized technology providers competing across small-molecule and biologic drug discovery. The top players in the industry are Pfizer Inc., GlaxoSmithKline plc, Merck & Co., Inc., Agilent Technologies Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Bayer AG, Abbott Laboratories, Shimadzu Corporation, AstraZeneca, Sanofi, Novartis AG, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and others.
The industry participants are inclined towards research collaborations and advanced technologies to improve target identification, molecule design, lead optimization, and development efficiency. Companies are increasingly focusing on artificial intelligence, machine learning, high-throughput screening, bioinformatics, computational modeling, genomics, and automated laboratories to identify promising therapeutic candidates faster and reduce the time required during early-stage research.
Recursion is a clinical-stage TechBio company developing an AI-native approach to drug discovery and development. Its Recursion OS integrates biology, chemistry, proprietary multimodal data, automated experimentation, and AI models within a unified platform. The company works across oncology, neuroscience, immunology, rare diseases, and other therapeutic areas through both internal programs and pharmaceutical partnerships.
In August 2026, Recursion announced that Genentech had advanced the companies' first neuroscience target into a joint early drug discovery program. The collaboration uses Recursion's AI-driven platform and large-scale biological datasets to identify and validate potential therapeutic targets, providing further evidence of how computational technologies are moving into pharmaceutical discovery workflows.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Cord Blood Banking Services Market Size, Share, Growth, Analysis, 2034
Bioburden Testing Market Size, Share, Growth, Forecast, 2034
Biopharmaceutical Contract Manufacturing Market Size, Share, 2034
Biological Safety Testing Products and Services Market Size, 2034
Medical Physics Market Size, Share, Growth, Analysis, Report, 2034
Blood Transfusion Market Size, Share, Growth, Forecast, 2034
We are featured on:
sales@straitsresearch.com